Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) Research & Development (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Research & Development data on record, last reported at $4.5 million in Q3 2025.

  • For Q3 2025, Research & Development rose 49.0% year-over-year to $4.5 million; the TTM value through Sep 2025 reached $18.1 million, up 51.14%, while the annual FY2024 figure was $13.0 million, 24.12% down from the prior year.
  • Research & Development reached $4.5 million in Q3 2025 per PLX's latest filing, down from $6.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $8.8 million in Q1 2022 and bottomed at $2.9 million in Q1 2024.
  • Average Research & Development over 5 years is $5.4 million, with a median of $5.6 million recorded in 2022.
  • Peak YoY movement for Research & Development: plummeted 50.62% in 2024, then surged 102.36% in 2025.
  • A 5-year view of Research & Development shows it stood at $7.6 million in 2021, then fell by 26.49% to $5.6 million in 2022, then crashed by 44.77% to $3.1 million in 2023, then surged by 32.95% to $4.1 million in 2024, then increased by 8.32% to $4.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $4.5 million in Q3 2025, $6.0 million in Q2 2025, and $3.5 million in Q1 2025.